rubella

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instance_of gptkb:disease
gptkbp:caused_by gptkb:rubella_virus
gptkbp:character_traits single serotype
gptkbp:clinical_trial mild illness in children
more severe in adults
gptkbp:common_name gptkb:German_measles
gptkbp:complications gptkb:congenital_rubella_syndrome
gptkbp:condition gptkb:multiple_sclerosis
deafness
cataracts
cardiac defects
thrombocytopenic purpura
gptkbp:contraindication pregnant women
immunocompromised individuals
gptkbp:diagnosis serological testing
gptkbp:diseases vaccination campaigns
common in unvaccinated populations
gptkbp:epidemiology declined due to vaccination
gptkbp:global_eradication_goal gptkb:2020_target_by_WHO
gptkbp:history first described in 1752
https://www.w3.org/2000/01/rdf-schema#label rubella
gptkbp:immunity_duration lifetime after infection
gptkbp:incubation_period 2 to 3 weeks
gptkbp:is_recognized_as gptkb:Physician
gptkbp:is_vulnerable_to gptkb:MMR_vaccine
rash
refrigerated
live attenuated vaccine
mild fever
rare allergic reactions
95% or higher
reduced incidence of disease
arthralgia
administered at 12-15 months
booster at 4-6 years
decreased congenital rubella syndrome cases
introduced in 1969
routine childhood vaccination
gptkbp:laboratory_confirmation PCR testing
Ig M antibody detection
gptkbp:nutritional_value gptkb:Togaviridae
gptkbp:prevalence worldwide
gptkbp:prevention vaccination
gptkbp:public_awareness important for vaccination
gptkbp:public_health_measure immunization programs
gptkbp:risk_management pregnant women
gptkbp:risk_of_transmission from mother to fetus
gptkbp:scientific_classification vaccine-preventable disease
gptkbp:screenings before pregnancy
gptkbp:symptoms fever
rash
lymphadenopathy
gptkbp:transmission airborne droplets
gptkbp:treatment supportive care
gptkbp:vaccine_administration_route subcutaneous injection
gptkbp:virus_genus gptkb:Rubivirus
gptkbp:bfsParent gptkb:M-M-R_II
gptkbp:bfsLayer 5